ABT-494 is a second generation Jak kinase inhibitor with high selectivity for Jak1 thereby minimizing the potential for side effects related to Jak2 and Jak3 inhibition. Here we describe preclinical ...

Background Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining a favorable safety profile and clinical efficacy in patients after 4 weeks of dosing with rheumatoid arthritis (RA ...

For further analysis, we purified a fusion protein (limitin–Ig) prepared from limitin and human immunoglobulin (Ig) from the supernatant of 293T cells transfected with the limitin–Ig/BOS plasmid.

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. The Krebs cycle byproduct itaconate has ...

View all available purchase options and get full access to this article.

Melanoma is a highly malignant tumor, that stands as the most lethal form of skin cancer and is characterized by notable phenotypic plasticity and intratumoral heterogeneity. Melanoma plasticity is ...

In one study, ruxolitinib (Jafaki), which targets JAK1 and JAK2, was tested in combination with Bristol Myers Squibb (BMS)’s anti-PD-1 drug nivolumab in patients with relapsing-refractory Hodgkin ...